Advanced

Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy

Ljungman, P.; Locasciulli, A.; de Soria, V. G.; Békássy, Albert LU ; Brinch, L.; Espigado, I.; Ferrant, A.; Franklin, I. M.; O'Riordan, J. and Rovira, M., et al. (2012) In Bone Marrow Transplantation 47(9). p.1217-1221
Abstract
This prospective study was initiated in 1993 with the aim to study late effects and responses to antiviral therapy in a cohort of hepatitis C virus (HCV)-infected patients. A total of 195 patients were included from 12 centers. In all, 134 patients had undergone allogeneic and 61 autologous hematopoietic SCT (HSCT). The median follow-up from HSCT is currently 16.8 years and the maximum 27.2 years. Overall 33 of 195 patients have died of which 6 died from liver complications. The survival probability was 81.6% and the cumulative incidence for death in liver complications was 6.1% at 20 years after HSCT. The cumulative incidence of severe liver complications (death from liver failure, cirrhosis and liver transplantation) was 11.7% at 20... (More)
This prospective study was initiated in 1993 with the aim to study late effects and responses to antiviral therapy in a cohort of hepatitis C virus (HCV)-infected patients. A total of 195 patients were included from 12 centers. In all, 134 patients had undergone allogeneic and 61 autologous hematopoietic SCT (HSCT). The median follow-up from HSCT is currently 16.8 years and the maximum 27.2 years. Overall 33 of 195 patients have died of which 6 died from liver complications. The survival probability was 81.6% and the cumulative incidence for death in liver complications was 6.1% at 20 years after HSCT. The cumulative incidence of severe liver complications (death from liver failure, cirrhosis and liver transplantation) was 11.7% at 20 years after HSCT. In all, 85 patients have been treated with IFN; 42 in combination with ribavirin. The sustained response rate was 40%. The rates of severe side effects were comparable to other patient populations and no patient developed significant exacerbations of GVHD. Patients receiving antiviral therapy had a trend toward a decreased risk of severe liver complications (odds ratio=0.33; P=0.058). HCV infection is associated with morbidity and mortality in long-term survivors after HSCT. Antiviral therapy can be given safely and might reduce the risk for severe complications. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Hepatitis C virus, antiviral therapy, late effects
in
Bone Marrow Transplantation
volume
47
issue
9
pages
1217 - 1221
publisher
Nature Publishing Group
external identifiers
  • wos:000308343200013
  • scopus:84865966560
ISSN
1476-5365
DOI
10.1038/bmt.2011.238
language
English
LU publication?
yes
id
09bfd333-8100-4f85-b469-b72bbd6a472b (old id 3147613)
date added to LUP
2012-11-01 09:32:05
date last changed
2017-09-10 03:17:35
@article{09bfd333-8100-4f85-b469-b72bbd6a472b,
  abstract     = {This prospective study was initiated in 1993 with the aim to study late effects and responses to antiviral therapy in a cohort of hepatitis C virus (HCV)-infected patients. A total of 195 patients were included from 12 centers. In all, 134 patients had undergone allogeneic and 61 autologous hematopoietic SCT (HSCT). The median follow-up from HSCT is currently 16.8 years and the maximum 27.2 years. Overall 33 of 195 patients have died of which 6 died from liver complications. The survival probability was 81.6% and the cumulative incidence for death in liver complications was 6.1% at 20 years after HSCT. The cumulative incidence of severe liver complications (death from liver failure, cirrhosis and liver transplantation) was 11.7% at 20 years after HSCT. In all, 85 patients have been treated with IFN; 42 in combination with ribavirin. The sustained response rate was 40%. The rates of severe side effects were comparable to other patient populations and no patient developed significant exacerbations of GVHD. Patients receiving antiviral therapy had a trend toward a decreased risk of severe liver complications (odds ratio=0.33; P=0.058). HCV infection is associated with morbidity and mortality in long-term survivors after HSCT. Antiviral therapy can be given safely and might reduce the risk for severe complications.},
  author       = {Ljungman, P. and Locasciulli, A. and de Soria, V. G. and Békássy, Albert and Brinch, L. and Espigado, I. and Ferrant, A. and Franklin, I. M. and O'Riordan, J. and Rovira, M. and Shaw, P. and Einsele, H.},
  issn         = {1476-5365},
  keyword      = {Hepatitis C virus,antiviral therapy,late effects},
  language     = {eng},
  number       = {9},
  pages        = {1217--1221},
  publisher    = {Nature Publishing Group},
  series       = {Bone Marrow Transplantation},
  title        = {Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy},
  url          = {http://dx.doi.org/10.1038/bmt.2011.238},
  volume       = {47},
  year         = {2012},
}